查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836842

精准医疗市场（按产品类型、应用和最终用户划分）－2025-2032 年全球预测

Precision Medicine Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

精准医疗市场预计到 2032 年将成长至 3,413.8 亿美元，复合年增长率为 11.73%。

主要市场统计数据
基准年2024年 1405.4亿美元
预计2025年 1559亿美元
预测年份：2032年 3413.8亿美元
复合年增长率（%） 11.73%

权威介绍，解释技术进步、临床工作流程和生态系统伙伴关係如何推动精准医疗进入主流医疗保健服务

对于寻求根据患者独特生物学特征制定治疗方案的医疗机构、生物製药创新者、诊断研发人员和医疗系统而言，精准医疗已从一个梦想概念演变为切实可行的必需品。基因测序、分子诊断和数据分析领域的最新进展，正在将重心从群体层面的干预转向有针对性的治疗方案，从而提高诊断准确性、优化治疗方法选择并缩短试验的治疗週期。如今，这些技术推动因素与不断变化的临床工作流程、支付方对价值证据的期望以及成熟的服务供应商生态系统相辅相成，从而加快了临床医生和研究人员获得洞察的时间。

随着相关人员从概念验证转向实用化，诊断、软体和治疗之间的相互作用正在创造新的经营模式和伙伴关係。伴随测试、基因面板和液态切片等诊断为药物开发和患者分层提供信息，而软体和数据分析则将原始分子数据转化为可临床操作的报告。从细胞和基因疗法到标靶治疗和基于 RNA 的方法的治疗创新越来越需要整合的诊断途径和专门的製造生态系统。因此，有关产品开发、商业化和供应链设计的策略选择取决于对技术依赖性、监管趋势和最终用户回应能力的细緻理解。本执行摘要为这些动态提供了一个框架，以帮助领导者确定投资优先顺序、降低营运风险并加速具有临床意义的采用。

深入分析融合诊断技术、不断变化的监管预期以及分散製造，这些正在从根本上重塑精准医疗策略

精准医疗领域正在经历几场变革时期，这些变革正在重塑技术创新、监管和商业化之间的相互关係。分子诊断、就地检验和液态切片平台与云原生分析的互通性日益增强，从而能够在即时检验时提供即时决策支援。这种融合促进了上游发现与下游临床应用之间的更紧密整合，形成了一个回馈迴路，从而加速了生物标记检验和治疗优化。其次，资料基础设施和分析技术日趋成熟，使得多中心协作研究能够透过联邦学习、隐私保护计算和可扩展的生物资讯学流程进行，而无需牺牲资料管治。因此，现在可以更有效地协调临床和现实世界数据集，以用于检验试验和上市后证据产生。

第三，法律规范和报销模式正转向临床效用和成本效益的证据，这要求诊断开发者和治疗申办者之间更紧密的合作。这些监管变革正在鼓励协作开发策略和新的报销模式，以奖励已证实的患者获益。第四，随着旨在支持细胞和基因疗法产能的合约开发与受託製造厂商(CDMO) 的出现，先进疗法的生产和供应链架构正朝着分散化、模组化和区域化的方向发展。这些转变降低了物流风险，并支持患者更快获得治疗，但也引入了新的品管和法规遵循要求。最后，付款人的期望和医疗系统采购惯例越来越倾向于能够在整个护理过程中展现出更佳疗效的整合解决方案，这迫使公司设计将诊断、分析和治疗途径整合成一个连贯的价值提案的产品。总而言之，这些转变迫使公司重新思考跨职能协作，投资于强大的数据策略，并追求灵活的生产和分销模式，以保持竞争力。

全面评估 2025 年关税变化和贸易政策动态将如何为精准医疗企业带来供应链风险、采购奖励和策略在地化压力。

2025年影响国际贸易和关税的政策行动将对整个精准医疗价值链产生累积效应，影响投入、製造成本和分销动态。试剂、定序耗材和高精度设备等关键零件的关税上调，可能会增加诊断实验室和製造商的采购成本。因此，投入成本的上升将挤压伴随诊断开发商和支持细胞和基因治疗供应链的契约製造製造商的利润率。这些压力将促使企业重新评估筹资策略，追求供应商多元化，并加速对维持成本和进度可预测至关重要的製造流程的在地化。

除了直接的成本影响外，关税环境还带来了时间和物流的不确定性，使资本规划和产能部署更加复杂。准备进行临床试验或扩大商业营运规模的公司可能会面临进口设备和材料的前置作业时间波动，这可能会延迟新检测平台的实施以及输液和生产设施的安装。因此，公司可能会增加关键任务物资的缓衝库存，或协商包含关税减免条款的长期供应商合约。此外，关税政策的变化可能会导致竞争力下降。拥有成熟区域製造地和垂直整合供应链的公司可能享有相对优势，而依赖跨国采购的公司则可能面临更大的营运摩擦。

关税也将影响战略伙伴关係和外国直接投资决策。企业可能会加快近岸外包进程，或寻求与当地製造商或诊断实验室建立合资企业，以规避贸易壁垒并保持市场进入。这种商业性和营运布局的再形成通常需要重新协商智慧财产权安排、技术转移计划和品质保证通讯协定，以确保跨司法管辖区的合规性。先前共用样本和设备的跨国联盟可能会采用其他共同研究模式，减少跨国货物流动，转而利用分散式资料分析和本地样本处理来维持研究的连续性。这些动态相结合，需要积极主动的供应链风险评估、情境规划和合约弹性，以维持专案进度并保护商业性前景。

细分主导的可操作洞察，将产品类型、临床应用和使用者工作流程结合起来，优先考虑精准医疗领域的投资和打入市场策略

要了解需求驱动因素，需要仔细细分产品类型、临床应用和最终用户，以确定哪些投资和重点营运能够产生最大的策略回报。诊断学进一步分为伴随诊断、基因检测、液态切片、分子诊断和就地检验；而治疗学则分为细胞和基因疗法、免疫疗法、蛋白质替代疗法、基于RNA的疗法和标靶小分子。伴随诊断严格遵循治疗开发时间表，并需要共同检验；基因检测服务依赖于强大的变异解读流程和合规框架；液态切片平台强调灵敏度和纵向监测；即时检测则优先考虑简便性和快速的临床应用。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 实施人工智慧和机器学习演算法，用于多组体学物标誌物发现和患者分层
  • 扩展次世代定序面板，用于罕见疾病诊断和个人化治疗决策
  • 数位双胞胎技术的出现，用于临床试验中的虚拟患者建模和精准治疗模拟
  • 将真实世界证据和健康经济成果整合到精准肿瘤药物开发策略中
  • 利用 CRISPR 和基因编辑平台进行体内单一基因疾病的校正并加速治疗流程
  • 针对查核点抑制剂和细胞疗法的新型免疫疗法的伴随诊断检测的开发
  • 使用穿戴式生物感测器和远端医疗对分层患者群体进行分散临床试验
  • 製药公司与数位健康Start-Ups建立策略伙伴关係，共同开发个人化护理途径

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章精准医疗市场（依产品类型）

  • 诊断
    • 伴随诊断
    • 基因检测
    • 液态生物检体
    • 分子诊断
    • 就地检验
  • 软体和数据分析
  • 治疗药物
    • 细胞疗法
    • 基因治疗
    • 免疫疗法
    • 蛋白质替代疗法
    • 基于RNA的治疗方法
    • 标靶治疗

第九章精准医疗市场的应用

  • 自体免疫疾病
  • 心臟病学
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 罕见疾病和遗传疾病
  • 呼吸系统疾病

第 10 章精准医疗市场（依最终使用者）

  • 生物製药和生物技术公司
  • 诊断实验室
  • 医院和诊所
  • 研究机构

第十一章 精准医疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 精准医疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 精准医疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie Inc.
    • Amgen Inc.
    • Aranscia, LLC
    • AstraZeneca PLC
    • biocrates life sciences ag
    • bioMerieux SA
    • Bristol-Myers Squibb Company
    • Caris Life Sciences
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • Guardant Health, Inc.
    • healthOme, Inc.
    • Hitachi High-Tech Corporation
    • Illumina, Inc.
    • Johnson & Johnson
    • Laboratory Corporation of America Holdings
    • Medtronic PLC
    • Merck KGaA
    • N-Power Medicine, Inc.
    • Natera Inc.
    • NeoGenomics, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Precision Medicine Group, LLC
    • QIAGEN NV
    • Quest Diagnostics Incorporated
    • Sanofi SA
    • Strata Oncology, Inc.
    • Tempus AI, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Thermo Fisher Scientific Inc.
    • ZS Associates, Inc.
Product Code: MRR-030EE48515D0

The Precision Medicine Market is projected to grow by USD 341.38 billion at a CAGR of 11.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 140.54 billion
Estimated Year [2025] USD 155.90 billion
Forecast Year [2032] USD 341.38 billion
CAGR (%) 11.73%

An authoritative introduction explaining why technological advances, clinical workflows and ecosystem partnerships are driving precision medicine into mainstream healthcare delivery

Precision medicine has evolved from an aspirational concept into a practical imperative for healthcare organizations, biopharmaceutical innovators, diagnostics developers and health systems that seek to align therapies with patient-specific biology. Recent advances in genomic sequencing, molecular diagnostics, and data analytics have shifted the balance from population-level interventions toward targeted approaches that improve diagnostic accuracy, optimize therapeutic selection and reduce trial-and-error treatment cycles. These technological enablers are now complemented by changing clinical workflows, payer expectations for value evidence, and a maturing ecosystem of service providers that reduce time-to-insight for clinicians and researchers alike.

As stakeholders move beyond proof-of-concept to operationalization, the interplay of diagnostics, software and therapeutics generates new business models and partnerships. Diagnostics modalities such as companion tests, genetic panels and liquid biopsies inform drug development and patient stratification, while software and data analytics transform raw molecular data into clinically actionable reports. Therapeutic innovations spanning cell and gene therapies to targeted and RNA-based approaches increasingly require integrated diagnostic pathways and specialized manufacturing ecosystems. Consequently, strategic choices about product development, commercialization, and supply chain design now hinge on a nuanced understanding of technical dependencies, regulatory trajectories and end-user readiness. This executive summary frames those dynamics to help leaders prioritize investments, mitigate operational risk and accelerate clinically meaningful adoption.

Detailed analysis of converging diagnostic technologies, evolving regulatory expectations and decentralizing manufacturing that are fundamentally reshaping precision medicine strategies

The landscape of precision medicine is undergoing several transformative shifts that collectively reconfigure how innovation, regulation and commercialization interconnect. First, diagnostic modalities have diversified and converged: molecular diagnostics, point-of-care testing and liquid biopsy platforms are increasingly interoperable with cloud-native analytics, enabling real-time decision support at the point of care. This convergence fosters tighter integration between upstream discovery and downstream clinical use, creating feedback loops that accelerate biomarker validation and therapeutic optimization. Second, data infrastructure and analytics have matured, with federated learning, privacy-preserving computation and scalable bioinformatics pipelines enabling multi-institutional collaboration without sacrificing data governance. As a result, clinical and real-world datasets can be harmonized more effectively for validation studies and post-market evidence generation.

Third, regulatory frameworks and reimbursement paradigms are shifting toward evidence of clinical utility and cost-effectiveness, requiring closer alignment between diagnostic developers and therapeutic sponsors. This regulatory evolution incentivizes co-development strategies and novel reimbursement models that reward demonstrated patient benefit. Fourth, manufacturing and supply-chain architectures for advanced therapies are decentralizing, with modular, regionalized facilities and contract development and manufacturing organizations (CDMOs) designed to support cell and gene therapy throughput. These shifts reduce logistical risk and support faster patient access but introduce new quality management and regulatory compliance requirements. Finally, payer expectations and health-system procurement practices increasingly favor integrated solutions that demonstrate improved outcomes across the care continuum, prompting companies to design offerings that combine diagnostics, analytics, and therapeutic pathways into coherent value propositions. Taken together, these shifts compel organizations to rethink cross-functional collaboration, invest in robust data strategies, and pursue flexible manufacturing and commercial models to remain competitive.

Comprehensive assessment of how 2025 tariff shifts and trade policy dynamics create supply chain risk, sourcing incentives and strategic localization pressures across precision medicine operations

Policy actions affecting international trade and tariffs in 2025 carry cumulative effects that extend across the precision medicine value chain, influencing inputs, manufacturing costs, and distribution dynamics. Increased duties on key components-such as reagents, sequencing consumables and high-precision instruments-tend to raise procurement costs for diagnostic laboratories and manufacturers. In turn, higher input costs can compress margins for developers of companion diagnostics and for contract manufacturers that support cell and gene therapy supply chains. These pressures incentivize organizations to reassess sourcing strategies, pursue supplier diversification, and accelerate localization of critical manufacturing steps to maintain cost and schedule predictability.

Beyond direct cost impacts, tariff environments introduce timing and logistical uncertainty that complicate capital planning and capacity deployment. Firms preparing clinical trials or scaling commercial operations face greater lead-time variability for imported equipment and materials, which can delay onboarding of new testing platforms or establishment of infusion and manufacturing suites. Consequently, companies are more likely to increase buffer inventories for mission-critical supplies or to negotiate long-term supplier agreements that include tariff mitigation clauses. Moreover, tariff policy shifts can provoke competitive displacement: firms with established regional manufacturing footprints or vertically integrated supply chains may gain relative advantage, while those dependent on cross-border sourcing confront higher operational friction.

Tariffs also influence strategic partnerships and foreign direct investment decisions. Organizations may accelerate nearshoring initiatives or pursue joint ventures with local manufacturers and diagnostic laboratories to circumvent trade barriers and preserve market access. This reshaping of commercial and operational footprints often requires renegotiation of intellectual property arrangements, tech transfer plans and quality assurance protocols to ensure compliance across jurisdictions. Finally, the cumulative impact of tariff policy extends to research collaborations: cross-border consortiums that previously shared samples and instrumentation may adopt alternative collaboration models that reduce cross-border movement of goods, instead leveraging distributed data analysis and local sample processing to maintain research continuity. Taken together, these dynamics require proactive supply-chain risk assessments, scenario planning and contractual flexibility to sustain program timelines and protect commercial prospects.

Actionable segmentation-led insights aligning product types, clinical applications and user workflows to prioritize investments and go-to-market strategies across precision medicine

Understanding demand drivers requires careful segmentation across product type, clinical application and end-user to identify where investment and operational focus generate the greatest strategic returns. Based on product type, the precision medicine ecosystem encompasses Diagnostics, Software & Data Analytics, and Therapeutics; Diagnostics further break down into companion diagnostics, genetic testing, liquid biopsy, molecular diagnostics, and point-of-care testing, while Therapeutics cover cell and gene therapies, immunotherapies, protein replacement, RNA-based modalities and targeted small molecules. Each product category follows a distinct development lifecycle and commercial pathway: companion diagnostics tightly follow therapeutic development timelines and require co-validation, genetic testing services depend on robust variant interpretation pipelines and compliance frameworks, liquid biopsy platforms emphasize sensitivity and longitudinal monitoring, and point-of-care testing prioritizes simplicity and rapid turnaround for clinical adoption.

Based on application, clinical demand centers on oncology, neurology, cardiology, infectious diseases, respiratory conditions, autoimmune disorders, and rare and genetic disorders, with oncology currently representing a major area for biomarker-driven approaches due to established links between genomic alterations and targeted therapeutic response. However, neurology and rare genetic disorders are gaining momentum as improved sequencing and biomarker discovery enable earlier and more precise interventions. Based on end user, adoption pathways vary between biopharmaceutical and biotechnology companies, diagnostic laboratories, hospitals and clinics, and academic and commercial research institutes, each with different procurement cycles, validation requirements and adoption incentives. Biopharmaceutical organizations often seek integrated companion diagnostic solutions to support clinical trials, diagnostic laboratories focus on throughput and reimbursement dynamics, hospitals and clinics require end-to-end workflow integration and clinical utility evidence, and research institutes prioritize flexibility and novel assay development. Recognizing these distinctions enables tailored go-to-market strategies, targeted evidence generation plans and partnership models that match product capabilities to specific clinical and operational needs.

Nuanced regional insights explaining how Americas, Europe-Middle East-Africa and Asia-Pacific dynamics affect regulatory strategy, adoption pathways and commercialization priorities

Regional dynamics shape how technologies are adopted, regulated and commercialized, making geographic strategy a central component of precision medicine planning. In the Americas, the United States ecosystem is characterized by an established venture and innovation infrastructure, a complex but maturing regulatory and reimbursement landscape, and dense clinical trial networks that support rapid technology validation and adoption. Canada and Latin American markets present distinct payer models and variable laboratory capacity, creating opportunities for partnerships that focus on assay validation, training and localized service delivery. In Europe, Middle East & Africa, regulatory harmonization across the European Union and regional initiatives to strengthen genomic literacy are facilitating cross-border clinical studies and multi-center evidence generation, while the Middle East and select African markets are investing in specialized centers of excellence to support rare disease diagnosis and advanced therapeutics; these investments often require bespoke regulatory navigation and capacity-building programs.

In Asia-Pacific, diverse market maturity ranges from highly developed healthcare and manufacturing ecosystems in countries with advanced biotech clusters to rapidly growing demand in emerging markets that prioritize access to affordable diagnostics and telehealth-enabled services. Regional supply-chain specialization in manufacturing and reagent production is notable, and strategic alliances with local partners can accelerate market access and regulatory approvals. Across all regions, interoperability of data systems, adherence to evolving privacy frameworks and alignment with local clinical practice patterns remain pivotal factors for successful deployment. Consequently, organizations should adopt regionally informed strategies that balance centralized R&D with decentralized validation and commercialization efforts, enabling both global standards compliance and local applicability.

Insightful competitive analysis highlighting how vertical integration, platform innovation and strategic partnerships are defining winners across diagnostics, analytics and therapeutics

Competitive dynamics in precision medicine reflect an increasingly collaborative and specialized landscape where established players, niche innovators and platform providers each play distinct roles. Diagnostic manufacturers that focus on companion tests and high-throughput sequencing instruments continue to invest in reducing turnaround time and enhancing analytical sensitivity, while software and data analytics providers are advancing interpretive algorithms, clinical decision support and integration with electronic health records to deliver actionable reports. Therapeutic developers across cell, gene, immunotherapy and RNA modalities are concentrating on robustness of manufacturing, logistics for personalized therapies and building evidence of clinical benefit through close collaboration with diagnostics developers.

Strategic moves across the ecosystem include vertical integration to secure critical supply inputs, targeted acquisitions to fill capability gaps in analytics or manufacturing, and co-development agreements that align diagnostic validation with therapeutic clinical programs. At the same time, a vibrant cohort of startups is pushing innovation in areas such as non-invasive monitoring, decentralized testing platforms and privacy-preserving analytics, creating potential partnership and acquisition targets for larger organizations. Contract manufacturing and service providers that specialize in advanced therapy manufacturing and supply-chain orchestration are gaining prominence as therapeutic pipelines transition from clinical trials to routine use. Investors and corporate development teams increasingly prioritize assets that demonstrate real-world clinical utility, regulatory readiness and scalable operational models, shifting competition toward ecosystems that combine technical capability with integrated evidence generation and commercial readiness.

Practical, high-impact recommendations for leaders to synchronize diagnostics and therapeutics, harden supply chains and build data-driven commercial strategies

Industry leaders must act with deliberate strategies that address technological complexity, regulatory evolution and operational fragility. First, align diagnostic development with therapeutic pipelines through formal co-development agreements and synchronized validation plans to ensure clinical utility evidence is generated in tandem with therapeutic trials. This approach reduces commercialization friction and enhances payer engagement by demonstrating linked clinical outcomes. Second, invest in resilient supply chains through multi-sourcing of critical reagents, regional manufacturing partnerships and contingency inventory strategies to mitigate tariff exposure and logistical disruptions. Third, prioritize data governance and interoperability by implementing standardized data models, adopting privacy-preserving computation methods and investing in clinician-facing decision support that integrates seamlessly with existing electronic health records.

Fourth, adopt flexible manufacturing strategies for advanced therapies that combine centralized expertise with regional capacity, enabling both quality consistency and faster patient access. Fifth, build commercial models that articulate clear value propositions for payers and health systems, emphasizing improved clinical pathways and measurable outcomes rather than standalone technology features. Sixth, pursue targeted partnerships with local diagnostic laboratories, research institutes and health systems to accelerate validation and adoption across diverse clinical settings. Finally, implement continuous scenario planning and regulatory intelligence functions to anticipate policy shifts, tariff changes and reimbursement trends, enabling rapid adjustments to operational plans and investment priorities. Collectively, these actions support scalable deployment, protect program timelines, and increase the probability of sustained clinical and commercial success.

Transparent research methodology combining primary stakeholder interviews, evidence mapping and scenario analysis to ensure reproducible, actionable insights for precision medicine leaders

The research underpinning this analysis integrates primary interviews, secondary literature synthesis and structured evidence mapping to ensure robust, actionable conclusions. Primary inputs include qualitative interviews with clinical leaders, diagnostics developers, therapeutic sponsors, manufacturing specialists and policy experts to capture operational realities and strategic priorities across the value chain. Secondary inputs encompass peer-reviewed literature, regulatory guidance documents, technical white papers and open-source clinical guidelines to contextualize technological trajectories and compliance requirements. Evidence mapping was employed to trace linkages between diagnostics capabilities, analytic workflows and therapeutic co-dependencies, allowing identification of choke points and opportunities for intervention.

Analytical methods combine comparative case analysis of recent co-development programs, supply-chain scenario modeling to assess exposure to trade policy shifts, and stakeholder-aligned value-mapping to prioritize investments by clinical impact and operational feasibility. Throughout the research process, attention was given to data provenance, reproducibility of analytic assumptions and alignment with prevailing regulatory frameworks. Limitations and areas for further in-depth study were identified, including the need for longitudinal post-deployment evidence on clinical utility, deeper cost-to-serve analyses for decentralized manufacturing models, and expanded stakeholder interviews in emerging geographies to refine regional implementation pathways.

A decisive conclusion emphasizing coordinated action across diagnostics, data and therapeutics to convert technical promise into sustained clinical and commercial impact

In conclusion, precision medicine now occupies a strategic intersection of technology, clinical practice and commercial strategy where coordinated action delivers outsized impact. The maturation of diagnostics, advances in software and analytics, and the proliferation of sophisticated therapeutics together create opportunities to improve patient outcomes and optimize care pathways. However, these opportunities come with operational complexity: supply-chain fragility, evolving regulatory expectations, and the need for demonstrable clinical utility require disciplined cross-functional collaboration and adaptive planning.

Organizations that succeed will be those that align diagnostic validation with therapeutic development, invest in resilient and regionally aware supply chains, deploy robust data governance and interoperability frameworks, and craft commercial models that articulate measurable value to payers and health systems. By adopting the strategic actions outlined here and engaging in targeted, regionally informed execution, leaders can translate technical promise into sustained clinical and commercial progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of artificial intelligence and machine learning algorithms for multiomic biomarker discovery and patient stratification
  • 5.2. Expansion of next-generation sequencing panels for rare disease diagnostics and personalized therapeutic decision making
  • 5.3. Emergence of digital twin technologies for virtual patient modeling and precision treatment simulation in clinical trials
  • 5.4. Integration of real-world evidence and health economic outcomes into precision oncology drug development strategies
  • 5.5. Adoption of CRISPR and gene editing platforms for in vivo correction of monogenic disorders and therapeutic pipeline acceleration
  • 5.6. Development of companion diagnostic assays for novel immunotherapies targeting checkpoint inhibitors and cell therapies
  • 5.7. Implementation of decentralized clinical trials leveraging wearable biosensors and telehealth for stratified patient cohorts
  • 5.8. Strategic partnerships between pharmaceutical companies and digital health startups to co-develop personalized care pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Precision Medicine Market, by Product Type

  • 8.1. Diagnostics
    • 8.1.1. Companion Diagnostics
    • 8.1.2. Genetic Testing
    • 8.1.3. Liquid Biopsy
    • 8.1.4. Molecular Diagnostics
    • 8.1.5. Point-of-Care Testing
  • 8.2. Software & Data Analytics
  • 8.3. Therapeutics
    • 8.3.1. Cell Therapy
    • 8.3.2. Gene Therapy
    • 8.3.3. Immunotherapy
    • 8.3.4. Protein Replacement Therapy
    • 8.3.5. RNA-Based Therapy
    • 8.3.6. Targeted Therapy

9. Precision Medicine Market, by Application

  • 9.1. Autoimmune Diseases
  • 9.2. Cardiology
  • 9.3. Infectious Diseases
  • 9.4. Neurology
  • 9.5. Oncology
  • 9.6. Rare & Genetic Disorders
  • 9.7. Respiratory Diseases

10. Precision Medicine Market, by End User

  • 10.1. Biopharmaceutical & Biotechnology Companies
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals & Clinics
  • 10.4. Research Institutes

11. Precision Medicine Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Precision Medicine Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Precision Medicine Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. AbbVie Inc.
    • 14.3.2. Amgen Inc.
    • 14.3.3. Aranscia, LLC
    • 14.3.4. AstraZeneca PLC
    • 14.3.5. biocrates life sciences ag
    • 14.3.6. bioMerieux S.A.
    • 14.3.7. Bristol-Myers Squibb Company
    • 14.3.8. Caris Life Sciences
    • 14.3.9. Exact Sciences Corporation
    • 14.3.10. F. Hoffmann-La Roche AG
    • 14.3.11. Gilead Sciences, Inc.
    • 14.3.12. Guardant Health, Inc.
    • 14.3.13. healthOme, Inc.
    • 14.3.14. Hitachi High-Tech Corporation
    • 14.3.15. Illumina, Inc.
    • 14.3.16. Johnson & Johnson
    • 14.3.17. Laboratory Corporation of America Holdings
    • 14.3.18. Medtronic PLC
    • 14.3.19. Merck KGaA
    • 14.3.20. N-Power Medicine, Inc.
    • 14.3.21. Natera Inc.
    • 14.3.22. NeoGenomics, Inc.
    • 14.3.23. Novartis AG
    • 14.3.24. Pfizer, Inc.
    • 14.3.25. Precision Medicine Group, LLC
    • 14.3.26. QIAGEN N.V.
    • 14.3.27. Quest Diagnostics Incorporated
    • 14.3.28. Sanofi SA
    • 14.3.29. Strata Oncology, Inc.
    • 14.3.30. Tempus AI, Inc.
    • 14.3.31. Teva Pharmaceutical Industries Ltd.
    • 14.3.32. Thermo Fisher Scientific Inc.
    • 14.3.33. ZS Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRECISION MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PRECISION MEDICINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. GCC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GCC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. GCC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. GCC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. GCC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 284. GCC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 285. GCC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. GCC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. GCC PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. GCC PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. G7 PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. G7 PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. G7 PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. G7 PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. G7 PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 318. G7 PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 319. G7 PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 320. G7 PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 321. G7 PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. G7 PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. G7 PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. G7 PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. NATO PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. NATO PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. NATO PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. NATO PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. NATO PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 330. NATO PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 331. NATO PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 332. NATO PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-20